APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 369, the Preserve Access to Affordable Pharmaceuticals Act S. 1315, the Drug Price Competition Act of 2009 H.R. 3777, the Drug Price Competition Act of 2009 H.R. 3962, Affordable Health Care for America Act, Section 2573, Protecting Consumer Access to Generic Drugs Act H.R. 3962, Affordable Heatlh Care for America Act, Section 2375, Licensure Pathway for Biosimilar Products H.R. 3590, the Patient Protection and Affordable Care Act, Title VII, Subtitle A, Biologics Price Competition and Innovation H.R. 4872, the Health Care and Education Reconciliation Act of 2010 pertaining to patent settlements between brand and generic pharmaceutical manufacturers
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.